Canada markets closed

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
8.07+0.02 (+0.25%)
At close: 01:09PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    BioSyent Announces Renewal of Normal Course Issuer Bid

    MISSISSAUGA, Ontario, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 740,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.88% of the Shares outstanding as of December 13, 2021. The NCIB will commence on De

  • Simply Wall St.

    Do Its Financials Have Any Role To Play In Driving BioSyent Inc.'s (CVE:RX) Stock Up Recently?

    BioSyent's (CVE:RX) stock is up by a considerable 21% over the past month. We wonder if and what role the company's...

  • GlobeNewswire

    BioSyent Releases Q3 and YTD 2021 Financial Results

    MISSISSAUGA, Ontario, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2021. Key highlights include: Third quarter (Q3) 2021 Net Revenues of $6,690,419 increased by 16% versus Q3 2020Year-to-date (YTD) 2021 Net Revenues of $21,399,562 increased by 29% versus YTD 2020Canadian Pharmaceutical Net Revenues in Q3 2021 of $6,409,809 increased by 17% versus Q3 2020YTD 2021 Canadian Pharma